Jeantet advises Getinge on the contemplated acquisition of Fluoptics, a leader in fluorescence imaging as an aid to surgery
Paris, 3 May 2022 – Jeantet has advised the Swedish listed global medical technology company Getinge AB (publ), with respect to the contemplated acquisition via its French subsidiary Getinge Infection Control SAS of 100% of the shares and voting rights of Fluoptics SAS a leader in fluorescence imaging as an aid to surgery.
The transaction is subject to certain condition precedent and closing conditions and is expected to be finalized before the end of the second quarter of 2022.
Fluorescence imaging helps to avoid post operative complications by securing a proper vascularization and helps to detect the parathyroid glands during Thyroid surgery. The objectives for Getinge are to complete its offer while enhancing Fluoptics products distribution and have Fluoptics to become a Center of Excellence for optics and visualization for Getinge.
Jeantet’s team is led by Karl Hepp de Sevelinges (Partner) and notably includes Marianne Chevallier (Counsel, Corporate/M&A), Nicolas Martin (Associate, Corporate/M&A), Paul Jolivet (Corporate/ M&A) Frédéric Sardain (Partner, IP), Sophie Boinnot (Associate, IP), Adrien Fourmon (Counsel, Regulatory), Anthony Bron (Associate, Regulatory), Thibault Mercier (Associate, Financing), Laure Asdrubal (Associate, Real Estate), Claire Allavena (Associate, GDPR).